Investigating Plasma Metabolomics and Gut Microbiota Changes Associated With Parkinson Disease
Open Access
- 27 May 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (10) , e213592
Abstract
Coffee intake is linked to a reduced risk of Parkinson disease (PD), but whether this effect is mediated by gut microbiota and metabolomic changes remains unclear. This study examines PD-associated metabolomic shifts, caffeine metabolism, and their connection to gut microbiome alterations in a multicenter study. We conducted an untargeted serum metabolomic assay using liquid chromatography with high-resolution mass spectrometry on an exploratory cohort recruited from National Taiwan University Hospital (NTUH). A targeted metabolomic assay focusing on caffeine and its 12 downstream metabolites was conducted and validated in an independent cohort from University Malaya Medical Centre (UMMC). In the exploratory cohort, the association of each caffeine metabolite with gut microbiota changes was investigated by metagenomic shotgun sequencing. A clustering-based approach was used to correlate microbiome changes with plasma caffeine metabolite level and clinical severity. Body mass index, antiparkinsonism medication use, and dietary habits (including coffee and tea intake) were recorded. Sixty-three patients with PD and 54 controls from NTUH formed the exploratory cohort while 36 patients with PD and 20 controls from UMMC served as an validation cohort to replicate the plasma caffeine findings. A total of 5,158 metabolites were detected from untargeted metabolomic analysis, with 3,131 having high confidence for analysis. Compared with controls, the abundance of 56 metabolites was significantly higher and that of 7 metabolites was significantly lower (adjusted p < 0.05 and log2 fold change >1) in patients with PD. Caffeine metabolism was significantly lower in patients with PD (p = 0.0013), and serum levels of caffeine and its metabolites negatively correlated with motor severity (p < 0.01). Targeted metabolomic analysis confirmed reduced levels of caffeine and its metabolites, including theophylline, paraxanthine, 1,7-dimethyluric acid, and 5-acetylamino-6-amino-3-methyluracil, in patients with PD; these findings were replicated in the validation cohort (p < 0.05). A clustering approach found that 56 microbiome species enriched in patients with PD negatively correlated with caffeine and its metabolites paraxanthine and theophylline (both p < 0.05), notably Clostridium sp000435655, Acetatifactor sp900066565, Oliverpabstia intestinalis, and Ruminiclostridium siraeum. This study identifies PD-related changes in microbial-caffeine metabolism compared with controls. Our findings offer insights for future functional research on caffeine-microbiome interactions in PD.Keywords
This publication has 41 references indexed in Scilit:
- Parkinson's diseaseThe Lancet, 2015
- Gut microbiota mediate caffeine detoxification in the primary insect pest of coffeeNature Communications, 2015
- Linking Smoking, Coffee, Urate, and Parkinson’s Disease – A Role for Gut Microbiota?Journal of Parkinson’s Disease, 2015
- Identification of novel biomarkers for Parkinson's disease by metabolomic technologiesJournal of Neurology, Neurosurgery & Psychiatry, 2015
- Anti‐inflammatory properties of intestinal Bifidobacterium strains isolated from healthy infantsMicrobiology and Immunology, 2011
- Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s diseaseEuropean Journal of Neurology, 2011
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor ChannelsMolecular Pharmacology, 2008
- Staging of brain pathology related to sporadic Parkinson’s diseaseNeurobiology of Aging, 2003
- Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's DiseaseJournal of Neuroscience, 2001